News from the FDA/CDC
Latest News
FDA to step up oversight of cosmetics, assess ‘forever chemicals’
The cosmetic products include makeup products, nail polishes, shaving creams, other grooming products, perfumes, face and body cleansers, hair...
Latest News
Despite recent uptick in cases, leprosy is very rare, expert says
Over the past several years, 150-250 cases of leprosy have been reported each year.
News from the FDA/CDC
Pneumococcal vaccine label adds injection-site risk
Reports of injection-site necrosis emerged after the vaccine had been approved by the FDA and was administered to a large, diverse, real-world...
News from the FDA/CDC
FDA approves first over-the-counter birth control pill
The product, OPill, is expected to be available early in 2024.
News from the FDA/CDC
FDA approves ritlecitinib for ages 12 and up for alopecia areata
It is the second JAK inhibitor approved for treating alopecia areata, following approval of baricitinib (Olumiant) in June 2022 for alopecia...
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.
News from the FDA/CDC
FDA OKs first-ever topical gene therapy, for rare skin disease
“Because it’s safe and easy to apply directly to wounds, it doesn’t require a lot of supporting technology or specialized expertise, making...
News from the FDA/CDC
CDC warns of Mpox resurgence in summer of 2023
Springtime and summertime gatherings and festivals could lead to renewed virus spread.
News from the FDA/CDC
FDA fast tracks potential CAR T-cell therapy for lupus
The cellular therapy depletes CD19-positive B cells with the goal of ‘‘resetting’’ the immune system to achieve durable remission.
Latest News
FMT in a pill: FDA approves second product to prevent C. diff recurrence
Clinicians now have two approved options for recurrent infections after antibiotic treatment.